EP1585987B1 — Use of adiponectin to diagnose malignancy
Assigned to Beth Israel Deaconess Medical Center Inc · Expires 2009-08-19 · 17y expired
What this patent protects
Methods aiding in the diagnosis of endometrial cancer or a risk of endometrial cancer are disclosed, in which the level of adiponectin is assessed in a test sample. Methods aiding in the diagnosis of an epithelial cancer or a risk of an epithelial cancer are also disclosed, in wh…
USPTO Abstract
Methods aiding in the diagnosis of endometrial cancer or a risk of endometrial cancer are disclosed, in which the level of adiponectin is assessed in a test sample. Methods aiding in the diagnosis of an epithelial cancer or a risk of an epithelial cancer are also disclosed, in which the level of adiponectin is assessed in a test sample. Representative epithelilal cancers include breast cancer, ovarian cancer, prostate cancer, leukemia and colon cancer. Also disclosed are methods of treating endometrial cancer or other epithelial cancers, comprising administering adiponectin or an adiponectin receptor agonist.
Drugs covered by this patent
- Mifeprex (MIFEPRISTONE) · Corcept Therap
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.